<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-09-24T09:08:33Z" sourceCorpus="COVID-19" filename="67189736" title="VBI-2902" url="https://en.wikipedia.org/wiki/VBI-2902">
	<text>
		<segment id="id67189736">N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.

 History 
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—&quot;enveloped virus-like particle (eVLP)&quot;. VBI-2901 is a &quot;trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins&quot;. VBI-2902 is a &quot;monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein&quot;. By March 9, the initial Phase 1/2 study of VBI-2902 was underway. VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.

 References 


 External links 

* https://www.vbivaccines.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/










</segment>
	</text>
</file>
